Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients


Karavasilis V, Papadimitriou C, Gogas H, Kouvatseas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, et al. Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clinical Breast Cancer [Internet]. 2016;16(4):291 - 298.e3.


Micro-Abstract We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy in women >65 years of age with early breast cancer. Elderly breast cancer patients derive clinical benefit comparable with that of younger patients, mainly at the cost of increased risk of hematological toxicity. © 2015 Elsevier Inc.


Cited By :1Export Date: 18 February 2017References: Yancik, R., Ries, L.A., Aging and cancer in America. Demographic and epidemiologic perspectives (2000) Hematol Oncol Clin North Am, 14, pp. 17-23;Freedman, R.A., Treatment of breast cancer in the elderly (2015) Curr Oncol Rep, 17, p. 51; Malik, M.K., Tartter, P.I., Belfer, R., Undertreated breast cancer in the elderly (2013) J Cancer Epidemiol, 2013, p. 893104; van de Water, W., Bastiaannet, E., Scholten, A.N., Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis (2014) Ann Surg Oncol, 21, pp. 786-794; Gennari, R., Curigliano, G., Rotmensz, N., Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients (2004) Cancer, 101, pp. 1302-1310; Du, X.L., Jones, D.V., Zhang, D., Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women (2005) J Gerontol A Biol Sci Med Sci, 60, pp. 1137-1144; Moylan, E.J., Connell, L.C., O'Reilly, S., Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer? (2014) J Clin Oncol, 32, pp. 605-606; Muss, H.B., Berry, D.A., Cirrincione, C., Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B (2007) Experience. J Clin Oncol, 25, pp. 3699-3704; Zauderer, M., Patil, S., Hurria, A., Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer (2009) Breast Cancer Res Treat, 117, pp. 205-210; Kummel, S., Krocker, J., Kohls, A., Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial (2006) Crit Rev Oncol Hematol, 58, pp. 166-175; Fountzilas, G., Skarlos, D., Dafni, U., Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group (2005) Ann Oncol, 16, pp. 1762-1771; Fountzilas, G., Dafni, U., Gogas, H., Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 (2008) Ann Oncol, 19, pp. 853-860; Gogas, H., Dafni, U., Karina, M., Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial (2012) Breast Cancer Res Treat, 132, pp. 609-619; Fountzilas, G., Dafni, U., Papadimitriou, C., Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial (2014) BMC Cancer, 14, p. 515; Hudis, C.A., Barlow, W.E., Costantino, J.P., Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system (2007) J Clin Oncol, 25, pp. 2127-2132; Gray, R., A class of K-sample tests for comparing the cumulative incidence of a competing risk (1988) Ann Stat, 16, pp. 1141-1154; Muss, H.B., Adjuvant treatment of elderly breast cancer patients (2007) Breast, 16, pp. S159-S165; Crivellari, D., Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group (2002) Tumori, 88, pp. S81-S82; Du, X.L., Lairson, D.R., Begley, C.E., Fang, S., Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort (2005) J Clin Oncol, 23, pp. 8620-8628; Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V., Barni, S., Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis (2012) Breast Cancer Res Treat, 135, pp. 335-346; Patt, D.A., Duan, Z., Fang, S., Hortobagyi, G.N., Giordano, S.H., Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk (2007) J Clin Oncol, 25, pp. 3871-3876; Robson, D., Verma, S., Anthracyclines in early-stage breast cancer: is it the end of an era? (2009) Oncologist, 14, pp. 950-958; Harder, H., Ballinger, R., Langridge, C., Ring, A., Fallowfield, L.J., Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making (2013) Psychooncology, 22, pp. 2729-2735; Cappellani, A., Di Vita, M., Zanghi, A., Prognostic factors in elderly patients with breast cancer (2013) BMC Surg, 13, p. S2; Barni, S., Cabiddu, M., Petrelli, F., Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls (2010) Exp Rev Anticancer Ther, 10, pp. 185-198